Please login to the form below

Not currently logged in
Email:
Password:

Apitope strengthens its board with new director

Dr William Jenkins joins the board following a 30-year career in clinical medicine

Dr William JenkinsClinical stage biotech Apitope has appointed Dr William Jenkins as its independent, non-executive director to its board.

Dr Jenkins has a wealth of pharmaceutical industry experience following a 30-year career in clinical medicine and research.

He has also served on several boards including Ablynx, Evotec and Acambis.

Stéphane Verdood, chairman of the board, said: “We are pleased to welcome William to Apitope’s board of directors.

“William’s extensive drug development expertise is a valuable addition as we seek to advance development of our potential first-in-class antigen-specific treatments targeted at autoimmune diseases.

“William has advised companies through various stages of growth to maturity and I know he will provide further strength and depth to the board.”

22nd March 2018

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Viseven

Viseven is a Global MarTech Services Provider for Pharma and Life Sciences Industries...

Latest intelligence

Mainimage2
The role of digital health technology tools in supporting medical adherence
How DHT-based digital interventions can help to support patients and improve adherence...
How To Tell A Better Silent Story
They say a picture's worth 1,000 words, which is incredibly helpful when telling a silent story....
Main image1
Global leaders in digital channels
Exploring why UK field teams are global leaders in digital channels is key to better understanding the changes in omnichannel engagement...